.

Horizon Pharma traded at $61.89 this Friday September 30th, decreasing $0.80 or 1.28 percent since the previous trading session. Looking back, over the last four weeks, Horizon Pharma lost 4.53 percent. Over the last 12 months, its price fell by 43.67 percent. Looking ahead, we forecast Horizon Pharma to be priced at 60.41 by the end of this quarter and at 53.33 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
61.89
Daily Change
-1.28%
Yearly
-43.67%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,767.00 -9.00 -0.24% 3.60%
AbbVie 134.21 -8.51 -5.96% 23.03%
Aerie Pharmaceuticals 15.13 0.01 0.07% 32.26%
ALKERMES 22.33 -0.13 -0.58% -27.69%
Amgen 225.40 -3.01 -1.32% 5.37%
AstraZeneca 9,944.00 11.00 0.11% 13.35%
Bristol-Myers Squibb 71.09 -0.62 -0.86% 19.46%
Cara Therapeutics 9.36 0.25 2.74% -38.62%
Coherus Biosciences 9.61 0.26 2.78% -41.83%
Endo International 0.10 -0.01 -5.47% -97.18%
Horizon Pharma 61.89 -0.80 -1.28% -43.67%
Jazz Pharmaceuticals 133.29 0.87 0.66% 2.55%
Eli Lilly 323.63 -6.66 -2.02% 40.96%
Merck & Co 86.12 -0.52 -0.60% 5.80%
Novartis 75.53 0.61 0.81% -0.70%
Prestige Brands 49.83 -0.34 -0.68% -10.07%
Pacira 53.19 -1.05 -1.94% -6.65%
Pfizer 43.76 -0.40 -0.91% 1.93%
Perrigo 35.66 -0.29 -0.81% -26.57%
Revance Therapeutics 27.00 1.33 5.18% -3.12%
Supernus Pharmaceuticals 33.85 0.57 1.71% 24.36%
Teva Pharmaceutical Industries 8.07 0.25 3.20% -16.80%
Bausch Health Companies Inc 9.54 0.03 0.32% -73.58%
Xeris Pharmaceuticals Inc 1.56 -0.03 -1.89% -36.84%
Zoetis 148.29 -2.66 -1.76% -24.42%

Indexes Price Day Year
USND 10576 -161.89 -1.51% -27.40%
US2000 1665 -10.21 -0.61% -25.74%

Horizon Pharma
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.